Update on the therapy for myelodysplastic syndrome.
Publication/Presentation Date
3-1-2009
Abstract
The myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders characterized by cytopenias. Patients have a risk of developing acute leukemia though most succumb to complications of low blood counts. Over the past decade many novel treatments have been developed and investigation of new agents is ongoing. In this article, we discuss the classification and prognostic systems that are used in MDS, the agents available for treatment of MDS as well as review supportive and palliative care options for patients who are not candidates for, or opt against, newer treatment strategies.
Volume
84
Issue
3
First Page
177
Last Page
186
ISSN
1096-8652
Published In/Presented At
Kasner, M. T., & Luger, S. M. (2009). Update on the therapy for myelodysplastic syndrome. American journal of hematology, 84(3), 177–186. https://doi.org/10.1002/ajh.21352
Disciplines
Medicine and Health Sciences
PubMedID
19195035
Department(s)
Hematology-Medical Oncology Division
Document Type
Article